Is Tumor Microenvironment Important for Targeted Therapy in Lung Cancer?

Overview

Journal Cancer Lett

Specialty Oncology

Date 2024 Sep 5

PMID 39236847

Authors

Shi-Yong Sun

Affiliations

Soon will be listed here.

References

Lu C, Gao Z, Wu D, Zheng J, Hu C, Huang D . Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect. J Immunother Cancer. 2024; 12(6). PMC: 11328648. DOI: 10.1136/jitc-2024-009165. View

Lahiri A, Maji A, Potdar P, Singh N, Parikh P, Bisht B . Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023; 22(1):40. PMC: 9942077. DOI: 10.1186/s12943-023-01740-y. View

Maynard A, McCoach C, Rotow J, Harris L, Haderk F, Kerr D . Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. Cell. 2020; 182(5):1232-1251.e22. PMC: 7484178. DOI: 10.1016/j.cell.2020.07.017. View

Jiang X, Xu Y, Huang M, Zhang L, Su M, Chen X . Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells. Acta Pharmacol Sin. 2017; 38(11):1512-1520. PMC: 5672073. DOI: 10.1038/aps.2017.123. View

Bearz A, Martini J, Jassem J, Kim S, Chang G, Shaw A . Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations. J Thorac Oncol. 2023; 18(11):1581-1593. DOI: 10.1016/j.jtho.2023.07.023. View

Liu X, Hong L, Nilsson M, Hubert S, Wu S, Rinsurongkawong W . Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. Lung Cancer. 2020; 149:33-40. PMC: 7577964. DOI: 10.1016/j.lungcan.2020.08.023. View

Shi P, Oh Y, Deng L, Zhang G, Qian G, Zhang S . Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation. Clin Cancer Res. 2017; 23(21):6567-6579. PMC: 5668147. DOI: 10.1158/1078-0432.CCR-17-1574. View

Lin K, Cheng J, Yang T, Li Y, Zhu B . EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB. Biochem Biophys Res Commun. 2015; 463(1-2):95-101. DOI: 10.1016/j.bbrc.2015.05.030. View

Qian G, Guo J, Vallega K, Hu C, Chen Z, Deng Y . Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors. Mol Cancer Res. 2021; 19(10):1622-1634. PMC: 8492505. DOI: 10.1158/1541-7786.MCR-21-0147. View

10.

Lim J, Lee E, Lee S, Cho H, Ahn D, Hwang Y . Current literature review on the tumor immune micro-environment, its heterogeneity and future perspectives in treatment of advanced non-small cell lung cancer. Transl Lung Cancer Res. 2023; 12(4):857-876. PMC: 10183402. DOI: 10.21037/tlcr-22-633. View

11.

Dominguez C, Tsang K, Palena C . Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies. Cell Death Dis. 2016; 7(9):e2380. PMC: 5059888. DOI: 10.1038/cddis.2016.297. View

12.

Xiao X, Zeng S, Li Y, Li L, Zhang J . Aspirin Suppressed PD-L1 Expression through Suppressing KAT5 and Subsequently Inhibited PD-1 and PD-L1 Signaling to Attenuate OC Development. J Oncol. 2022; 2022:4664651. PMC: 8983188. DOI: 10.1155/2022/4664651. View

13.

Cooper A, Sequist L, Lin J . Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. 2022; 19(8):499-514. PMC: 9621058. DOI: 10.1038/s41571-022-00639-9. View

14.

Liu L, Wang C, Li S, Bai H, Wang J . Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review. Transl Lung Cancer Res. 2021; 10(9):3823-3839. PMC: 8512456. DOI: 10.21037/tlcr-21-572. View

15.

Han R, Hao S, Lu C, Zhang C, Lin C, Li L . Aspirin sensitizes osimertinib-resistant NSCLC cells in vitro and in vivo via Bim-dependent apoptosis induction. Mol Oncol. 2020; 14(6):1152-1169. PMC: 7266273. DOI: 10.1002/1878-0261.12682. View